Photobiomodulation enhances nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson's disease

Parkinsonism and Related Disorders

Volumn 18, Issue 5, 2012, Pages 469-476

  Peoples, Cassandra ^a   Spana, Sharon ^a   Ashkan, Keyoumars ^c   Benabid, Alim Louis ^b   Stone, Jonathan ^a   Baker, Gary E ^d   Mitrofanis, John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CEA LETI   (France)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d CITY UNIVERSITY   (United Kingdom)

Author keywords

Hypothalamus; Neuroprotection; Periaqueductal grey matter; Substantia nigra; Zona incerta

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL COUNT; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC NERVE CELL; HYPERTHERMIC THERAPY; HYPOTHALAMUS; IMMUNOCHEMISTRY; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PERIAQUEDUCTAL GRAY MATTER; PHOTOBIOMODULATION; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS COMPACTA; SURVIVAL; ZONA INCERTA;

ANALYSIS OF VARIANCE; ANIMALS; CELL COUNT; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; INFRARED RAYS; MALE; MICE; MICE, INBRED BALB C; PARKINSONIAN DISORDERS; PERIAQUEDUCTAL GRAY; SUBSTANTIA NIGRA; SUBTHALAMUS; TYROSINE 3-MONOOXYGENASE;

EID: 84861193198     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.01.005     Document Type: Article

References (27)

1. Desmet K.D.P.D., Corry J.J., Eells J.T., Wong-Riley M.T.T., Henry M.M., Buchmann E.V., et al. Clinical and experimental applications of NIR-LED photobiomodulation. Photomed Laser Surg 2006, 24:121-128.
2. Hamblin M.R., Demidova T.M. Mechanisms of low level light therapy. Proc SPIE 2006, 6140:614001-614012.
3. Natoli R.Z.Y., Valter K., Bisti S., Eells J., Stone J. Gene and noncoding RNA regulation underlying photoreceptor protection: microarray study of dietary antioxidant saffron and photobiomodulation in rat retina. Mol Vis 2010, 16:1801-1822.
4. Oron A., Oron U., Chen J., Eilam A., Zhang C., Sadeh M., et al. Low-level laser therapy applied transcranially to rats after induction of stroke significantly reduces long-term neurological deficits. Stroke 2006, 37:2620-2624.
5. Detaboada L., Ilic S., Leichliter-Martha S., Oron U., Oron A., Streeter J. Transcranial application of low-energy laser irradiation improves neurological deficits in rats following acute stroke. Lasers Surg Med 2006, 38:70-73.
6. Lapchak P.A., Wei J., Zivin J.A. Transcranial infrared laser therapy improves clinical rating scores after Embolic strokes in rabbits. Stroke 2004, 35:1985-1988.
7. Shaw V.E., Spana S., Ashkan K., Benabid A.L., Stone J., Baker G.E., et al. Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment. J Comp Neurol 2010, 518:25-40.
8. Lampl Y., Zivin J.A., Fisher M., Lew R., Welin L., Dahlof B., et al. Infrared laser therapy for ischemic stroke: a New treatment Strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke 2007, 38:1843-1849.
9. Naeser M.A., Saltmarche A., Krengel M.H., Hamblin M.R., Knight J.A. Improved Cognitive Function after Transcranial, light-emitting diode treatments in chronic, Traumatic brain injury: two case reports. Photomed Laser Surg 2011, 29:351-358.
10. Schiffer F., Johnston A.L., Ravichandran C., Polcari A., Teicher M.H., Webb R.H., et al. Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety. Beh Brain Functions 2009, 5:46.
11. Meredith GE, Totterdell S, Beales M, Meshul CK. Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp Neurol; 219: 334-340.
12. Pothakos K., Kurz M.J., Lau Y.S. Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. BMC Neurosci 2009, 10:1471-2202.
13. Schinitu N, Frau L, Ibba M, Garau A, Carboni E, Carta AR. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotoxicity Res;16:127-139.
14. Wallace B.A., Ashkan K., Heise C.E., Foote K.D., Torres N., Mitrofanis J., et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 2007, 130:2129-2145.
15. Ma J., Shaw V.E., Mitrofanis J. Does melatonin help save dopaminergic cells in MPTP-treated mice?. Parkinsonism Relat Disord 2009, 15:307-314.
16. Shaw V.E., Keay K.A., Ashkan K., Benabid A.L., Mitrofanis J. Dopaminergic cells in the periaqueductal grey matter of MPTP-treated monkeys and mice; patterns of survival and effect of deep brain stimulation and lesion of the subthalamic nucleus. Parkinsonism Relat Disord 2010, 16:338-344.
17. Rinne J.O. Nigral degeneration in Parkinson's disease. Mov Disord 1993, 8(Suppl 1):S31-S35.
18. Fitzpatrick E., Ashkan K., Wallace B.A., Benabid A.L., Mitrofanis J. Differential survival patterns among midbrain dopaminergic cells of MPTP-treated monkeys and 6OHDA-lesioned rats. Anat Embryol (Berl) 2005, 210:101-123.
19. Paxinos G., Franklin K. The mouse brain in sterotaxic coordinates 2001, Academic Press, California USA. 2nd ed.
20. Lu J.J.T., Jhou T.C., Saper C.B. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci 2006, 26:193-202.
21. Paul G.M.W., Rein S., Harnack D., Winter C., Hosmann K., Morgenstern R., et al. Removal of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson disease. Exp Neurol 2004, 185:272-280.
22. Huot P., Lévesque M., Parent A. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain 2007, 130:222-232.
23. Tatton W.G., Kwan M.M., Verrier M.C., Seniuk N.A., Theriault E. MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells. Brain Res Bull 1990, 527:21-31.
24. Bjorklund A., Rosenblad C., Winkler C., Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 1997, 4:186-200.
25. Martin M.M.M., Leon J., Escames G., Khaldy H., Acuna-Castroviejo D. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 2002, 34:348-357.
26. Yeager R.L., Oleske D.A., Sanders R.A., Watkins J.B., Eells J.T., Henshel D.S. Melatonin as a principal component of red light therapy. Med Hypotheses 2007, 69:372-376.
27. Zeitzer J.M.K.R., Czeisler C.A. Photopic transduction implicated in human circadian entrainment. Neurosci Lett 1997, 232:135-138.